U.S. Markets

FDA approves Lilly's (LLY) Onswik, a once-weekly basal insulin injection treatment for adults living with type 2 diabetes

StockNow breaking-news AI analysis

The US FDA approved Eli Lilly's Onswik, a once-weekly basal insulin injection treatment designed for adult patients living with type 2 diabetes.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more